JP2020536068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536068A5 JP2020536068A5 JP2020517983A JP2020517983A JP2020536068A5 JP 2020536068 A5 JP2020536068 A5 JP 2020536068A5 JP 2020517983 A JP2020517983 A JP 2020517983A JP 2020517983 A JP2020517983 A JP 2020517983A JP 2020536068 A5 JP2020536068 A5 JP 2020536068A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- weeks
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229960003301 nivolumab Drugs 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000002411 adverse Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010027476 Metastases Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N C[C@H](C(CC1)CCC1c1c(cc(cc2)F)c2ncc1)C(Nc(cc1)ccc1Cl)=O Chemical compound C[C@H](C(CC1)CCC1c1c(cc(cc2)F)c2ncc1)C(Nc(cc1)ccc1Cl)=O KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565819P | 2017-09-29 | 2017-09-29 | |
| US62/565,819 | 2017-09-29 | ||
| US201762569766P | 2017-10-09 | 2017-10-09 | |
| US62/569,766 | 2017-10-09 | ||
| US201762580219P | 2017-11-01 | 2017-11-01 | |
| US62/580,219 | 2017-11-01 | ||
| US201762609210P | 2017-12-21 | 2017-12-21 | |
| US62/609,210 | 2017-12-21 | ||
| US201862642711P | 2018-03-14 | 2018-03-14 | |
| US62/642,711 | 2018-03-14 | ||
| US201862678490P | 2018-05-31 | 2018-05-31 | |
| US62/678,490 | 2018-05-31 | ||
| PCT/US2018/053443 WO2019067913A1 (en) | 2017-09-29 | 2018-09-28 | COMPOSITIONS AND METHODS OF TREATING CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536068A JP2020536068A (ja) | 2020-12-10 |
| JP2020536068A5 true JP2020536068A5 (https=) | 2021-11-04 |
| JP7341130B2 JP7341130B2 (ja) | 2023-09-08 |
Family
ID=65902748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517983A Active JP7341130B2 (ja) | 2017-09-29 | 2018-09-28 | 癌を治療するための組成物および治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11351163B2 (https=) |
| EP (1) | EP3691643A4 (https=) |
| JP (1) | JP7341130B2 (https=) |
| KR (1) | KR102760684B1 (https=) |
| CN (1) | CN111386117A (https=) |
| WO (1) | WO2019067913A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113967253A (zh) * | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| US20160362489A1 (en) * | 2015-04-28 | 2016-12-15 | Bristol-Myers Squibb Company | Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody |
| EP3288982A1 (en) | 2015-04-28 | 2018-03-07 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| WO2024064668A1 (en) * | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| DK1141028T3 (da) | 1998-12-23 | 2010-05-25 | Pfizer | Humane monoklonale antistoffer til CTLA-4 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| EP1261376A1 (en) | 2000-01-27 | 2002-12-04 | Genetics Institute, LLC | Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| EA201691376A1 (ru) * | 2014-02-04 | 2017-01-30 | Пфайзер Инк. | Комбинация антагониста pd-1 и ингибитора vegfr для лечения рака |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| UY36391A (es) * | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| EP3370699A1 (en) | 2015-11-04 | 2018-09-12 | Incyte Corporation | Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
-
2018
- 2018-09-28 US US16/649,277 patent/US11351163B2/en active Active
- 2018-09-28 CN CN201880077408.5A patent/CN111386117A/zh active Pending
- 2018-09-28 WO PCT/US2018/053443 patent/WO2019067913A1/en not_active Ceased
- 2018-09-28 JP JP2020517983A patent/JP7341130B2/ja active Active
- 2018-09-28 EP EP18861598.3A patent/EP3691643A4/en active Pending
- 2018-09-28 KR KR1020207011965A patent/KR102760684B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088662A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| JP2020536068A5 (https=) | ||
| JP2019501204A5 (https=) | ||
| JP2019517549A5 (https=) | ||
| US9682082B2 (en) | Combinations of AKT and MEK inhibitor compounds, and methods of use | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2018519324A5 (https=) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2016529285A5 (https=) | ||
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| US20180221382A1 (en) | Inhibition of mk2 in the treatment of cancer | |
| JP2019524888A5 (https=) | ||
| JP2022501332A5 (https=) | ||
| JP2021511344A5 (https=) | ||
| JP2021152002A5 (https=) | ||
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| US9566334B2 (en) | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
| RS62560B1 (sr) | Antitumorski lek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta | |
| JP2013227347A5 (https=) |